ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Kemas kini terakhir: 21 jam lalu

780.67

1.39 (0.18%)

  • 1H 0.18%
  • 5H -1.82%
  • 1B 1.40%
  • 6B 2.04%
  • Tahun Ke Tarikh 0.33%
  • 1T -14.96%
  • 5T 367.78%
Penutupan Terdahulu 779.28
Buka 780.46
Jumlah Dagangan 1,415,890
Purata Dagangan (3B) 4,071,744
Modal Pasaran 700,835,561,472
Harga / Pendapatan (P/E TTM) 63.68
Harga / Pendapatan (P/E Ke hadapan) 35.59
Harga / Jualan (P/S) 14.29
Harga / Buku (P/B) 44.16
Julat 52 Minggu
677.09 (-13%) — 972.53 (24%)
Tarikh Pendapatan 7 Aug 2025
Hasil Dividen (DY TTM) 0.53%
Margin Keuntungan 22.67%
Margin Operasi (TTM) 42.49%
EPS Cair (TTM) 12.25
Pertumbuhan Hasil Suku Tahunan (YOY) 45.20%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 23.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 243.61%
Nisbah Semasa (MRQ) 1.37
Aliran Tunai Operasi (OCF TTM) 9.32 B
Aliran Tunai Bebas Leveraj (LFCF TTM) -1.82 B
Pulangan Atas Aset (ROA TTM) 16.45%
Pulangan Atas Ekuiti (ROE TTM) 77.28%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menurun Bercampur
Drug Manufacturers - General (Global) Menurun Bercampur
Stok Eli Lilly and Company Menurun Menaik

AISkor Stockmoo

1.6
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal 0.5
Purata 1.63

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
LLY 701 B 0.53% 63.68 44.16
NVO 316 B 2.33% 18.64 14.02
NVS 244 B 3.19% 19.11 6.23
MRK 203 B 2.95% 11.76 4.11
JNJ 375 B 2.38% 17.35 4.81
ABBV 334 B 3.37% 80.54 237.28

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Orang Dalam 0.16%
% Dimiliki oleh Institusi 84.08%

Pemilikan

Nama Tarikh Syer Dipegang
Lilly Endowment Inc 31 Mar 2025 96,016,978
1,181.451,181.45937.10937.10692.75692.75448.40448.40204.05204.05Harga Sasaran MedianQ1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
677.09 (-13%) — 972.53 (24%)
Julat Harga Sasaran
700.00 (-10%) — 1,124.00 (-99%)
Tinggi 1,124.00 (Morgan Stanley, 43.98%) Beli
Median 955.50 (22.40%)
Rendah 700.00 (HSBC, -10.33%) Jual
Purata 945.50 (21.11%)
Jumlah 5 Beli, 1 Jual
Harga Purata @ Panggilan 795.19
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Guggenheim 20 Jun 2025 936.00 (19.90%) Beli 762.73
14 Apr 2025 928.00 (18.87%) Beli 754.35
UBS 02 May 2025 1,050.00 (34.50%) Beli 823.62
HSBC 28 Apr 2025 700.00 (-10.33%) Jual 877.29
Cantor Fitzgerald 22 Apr 2025 975.00 (24.89%) Beli 827.54
Morgan Stanley 09 Apr 2025 1,124.00 (43.98%) Beli 753.71
Goldman Sachs 08 Apr 2025 888.00 (13.75%) Beli 726.24

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
23 Jun 2025 Pengumuman Lilly declares third-quarter 2025 dividend
22 Jun 2025 Pengumuman Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
21 Jun 2025 Pengumuman Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
17 Jun 2025 Pengumuman Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
16 Jun 2025 Pengumuman Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
02 Jun 2025 Pengumuman Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
02 Jun 2025 Pengumuman Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
29 May 2025 Pengumuman Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
27 May 2025 Pengumuman Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
22 May 2025 Pengumuman Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
21 May 2025 CNBC Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
21 May 2025 Pengumuman Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
19 May 2025 CNBC Novo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli Lilly
12 May 2025 CNBC Trump's plan to slash drug prices may struggle to get off the ground – here's what to know 
12 May 2025 CNBC Trump signs order aiming to cut some U.S. drug prices to match lower ones abroad
11 May 2025 Pengumuman Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
09 May 2025 Pengumuman Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
08 May 2025 Pengumuman Lilly announces transitions in executive leadership
05 May 2025 CNBC Trump signs order to boost domestic drug manufacturing as pharma tariffs loom
05 May 2025 Pengumuman Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy Division
05 May 2025 Pengumuman Lilly declares second-quarter 2025 dividend
02 May 2025 Pengumuman Lilly to participate in Bank of America Securities 2025 Healthcare Conference
01 May 2025 CNBC CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
01 May 2025 Pengumuman Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
01 May 2025 CNBC Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
01 May 2025 CNBC Eli Lilly CEO says company can help 'respond' to national security concerns around essential drugs as tariffs loom
29 Apr 2025 CNBC Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
29 Apr 2025 Pengumuman Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
28 Apr 2025 Pengumuman Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
25 Apr 2025 CNBC Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
24 Apr 2025 CNBC Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
23 Apr 2025 CNBC Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
17 Apr 2025 Pengumuman Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
17 Apr 2025 Pengumuman Lilly confirms date and conference call for first-quarter 2025 financial results announcement
17 Apr 2025 CNBC Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
14 Apr 2025 CNBC Pfizer scraps daily weight loss pill after liver injury in one patient
11 Apr 2025 CNBC Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
Papar semua
Hasil Dividen (DY TTM) 0.53%
Purata Hasil Dividen 5T 1.10%
Nisbah Pembayaran 43.94%
Jangkaan Pembayaran Dividen Seterusnya Dec 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
14 Feb 2025 09 Dec 2024 10 Mar 2025 1.5 Tunai
15 Nov 2024 28 Oct 2024 10 Dec 2024 1.3 Tunai
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 Tunai
15 May 2024 06 May 2024 10 Jun 2024 1.3 Tunai
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 Tunai
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 Tunai
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 Tunai
12 May 2023 01 May 2023 09 Jun 2023 1.13 Tunai
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 Tunai
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 Tunai
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 Tunai
13 May 2022 02 May 2022 10 Jun 2022 0.98 Tunai
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 Tunai
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 Tunai
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 Tunai
13 May 2021 03 May 2021 10 Jun 2021 0.85 Tunai
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 Tunai
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 Tunai
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 Tunai
14 May 2020 04 May 2020 10 Jun 2020 0.74 Tunai
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 Tunai
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 Tunai
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 Tunai
16 May 2019 07 May 2019 10 Jun 2019 0.645 Tunai
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 Tunai
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 Tunai
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 Tunai
16 May 2018 07 May 2018 08 Jun 2018 0.5625 Tunai
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 Tunai
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 Tunai
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 Tunai
11 May 2017 01 May 2017 09 Jun 2017 0.52 Tunai
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 Tunai
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 Tunai
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 Tunai
11 May 2016 02 May 2016 10 Jun 2016 0.51 Tunai
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 Tunai
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 Tunai
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 Tunai
14 May 2015 04 May 2015 10 Jun 2015 0.5 Tunai
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 Tunai
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 Tunai
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 Tunai
13 May 2014 05 May 2014 10 Jun 2014 0.49 Tunai
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 Tunai
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 Tunai
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 Tunai
14 May 2013 03 May 2013 10 Jun 2013 0.49 Tunai
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 Tunai
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 Tunai
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 Tunai
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 Tunai
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 Tunai
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 Tunai
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 Tunai
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 Tunai
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 Tunai
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 Tunai
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 Tunai
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 Tunai
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 Tunai
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 Tunai
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 Tunai
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 Tunai
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 Tunai
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 Tunai
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 Tunai
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 Tunai
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 Tunai
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 Tunai
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 Tunai
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 Tunai
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 Tunai
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 Tunai
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 Tunai
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 Tunai
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 Tunai
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 Tunai
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 Tunai
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 Tunai
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 Tunai
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 Tunai
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 Tunai
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 Tunai
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 Tunai
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 Tunai
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 Tunai
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 Tunai
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 Tunai
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 Tunai
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 Tunai
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 Tunai
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 Tunai
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 Tunai
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 Tunai
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 Tunai
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 Tunai
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 Tunai
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 Tunai
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 Tunai
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 Tunai
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 Tunai
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 Tunai
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 Tunai
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 Tunai
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 Tunai
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 Tunai
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 Tunai
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 Tunai
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 Tunai
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 Tunai
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 Tunai
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 Tunai
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 Tunai
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 Tunai
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 Tunai
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 Tunai
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.50 1 0.19
2024 5.20 4 0.67
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
Papar semua
806.45806.45790.66790.66774.86774.86759.07759.07743.28743.28Jun 24Jun 24Jun 25Jun 25Jun 26Jun 26Jun 27Jun 27Jun 30Jun 30Jul 1Jul 1Jul 2Jul 2Jul 3Jul 3

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
6.0006.0004.0004.0002.0002.0000.0000.000-2.000-2.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda